Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01693614 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT01693614 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 72 participants.
The verdict
NCT01693614, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
This is a phase II study evaluating the safety, tolerability and efficacy of BKM120 in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) or follicular lymphoma (FL).
Interventions
- DRUG Buparlisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2013-02-28 |
| Est. Completion | 2017-07-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01693614
The ClinicalTrials.gov registry entry for NCT01693614 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Buparlisib is the first listed.
NCT01693614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01693614 about?
NCT01693614 is a clinical study titled "Safety and Efficacy of BKM120 in Relapsed and Refractory NHL". This is a phase II study evaluating the safety, tolerability and efficacy of BKM120 in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) or follicular lymphoma (FL).
What is the current status of trial NCT01693614?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2013-02-28. Estimated completion is 2017-07-21.
What interventions are being tested in trial NCT01693614?
The interventions under investigation include: Buparlisib (DRUG).
Who is sponsoring clinical trial NCT01693614?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.